HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Fate Therapeutics, Inc provides biotechnology services. The company researches and develops therapies to repair and regenerate body tissues with the help of stem cells.
| Market Cap | 1.844 Billion | Shares Outstanding | 75.59 Million | Avg Volume | 1.049 Million |
| 1-Yr BETA vs S&P TR | 1.825 | Current Ratio | 7.53 | Quick Ratio | 7.53 |
| Fate Therapeutics Inc Chart by YCharts | |
| Yahoo! Finance | finviz |
| SEC Web Site | SEC DEF 14A Filings |
Please sign in first
none
92.1 Thousand total shares from 7 transactions
75 Thousand total shares from 3 transactions
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
WOLCHKO J SCOTT PRESIDENT AND CEO |
|
419,969 | 2020-01-08 | 7 |
|
SHOEMAKER DANIEL D CHIEF SCIENTIFIC OFFICER |
|
143,091 | 2020-01-08 | 5 |
|
TAHL CINDY GENERAL COUNSEL AND SECRETARY |
|
99,518 | 2020-01-08 | 4 |
|
VALAMEHR BAHRAM CHIEF DEVELOPMENT OFFICER |
|
86,058 | 2020-01-08 | 2 |
|
WEYER CHRISTIAN EVP, RESEARCH & DEVELOPMENT |
|
13,760 | 2019-12-31 | 0 |
|
0 | 2019-12-24 | 1 | |
|
AGARWAL SHEFALI CHIEF MEDICAL OFFICER |
|
58,276 | 2019-12-02 | 2 |
|
696,378 | 2019-10-29 | 0 | |
|
0 | 2019-09-17 | 1 | |
|
2,310,432 | 2019-07-31 | 9 | |
|
ENYEDY MARK J CHIEF EXECUTIVE OFFICER |
|
488,998 | 2019-07-01 | 0 |
|
0 | 2019-06-12 | 1 | |
|
0 | 2019-05-08 | 1 | |
|
0 | 2019-05-08 | 1 | |
|
0 | 2019-05-03 | 3 | |
|
ABBOT STEWART CHIEF DEVELOPMENT OFFICER |
|
64,917 | 2018-05-15 | 0 |
|
MULTANI PRATIK S CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2018-02-08 | 0 |
|
STORGARD CHRIS CHIEF MEDICAL OFFICER |
|
0 | 2018-01-16 | 0 |
|
FLYNN PETER D EVP, HEAD OF GLOBAL DEV |
|
0 | 2017-10-13 | 0 |
|
FATE THERAPEUTICS INC CHIEF SCIENTIFIC OFFICER |
|
103,816 | 2016-01-08 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
| 2020-01-08 | A | 90,000 | a | 90,000 | 143,091.00 | direct | |||
| 2020-01-08 | A | 90,000 | a | 90,000 | 86,058.00 | direct | |||
| 2020-01-08 | A | 90,000 | a | 90,000 | 99,518.00 | direct | |||
| 2020-01-08 | A | 219,000 | a | 219,000 | 419,969.00 | direct | |||
| 2020-01-08 | S | 5,700 | $20.70 | d | 143,091 | 143,091.00 | direct | ||
| 2020-01-08 | S | 5,700 | $20.69 | d | 86,058 | 86,058.00 | direct | ||
| 2020-01-08 | S | 5,700 | $20.72 | d | 99,518 | 99,518.00 | direct | ||
| 2020-01-08 | A | 66,000 | a | 419,969 | 419,969.00 | direct | |||
| 2020-01-08 | A | 25,000 | a | 148,791 | 143,091.00 | direct | |||
| 2020-01-08 | A | 25,000 | a | 91,758 | 86,058.00 | direct | |||
| 2020-01-08 | A | 25,000 | a | 105,218 | 99,518.00 | direct | |||
| 2019-12-30 | S | 100 | $20.34 | d | 123,791 | 123,791.00 | direct | yes | |
| 2019-12-30 | S | 24,900 | $19.49 | d | 123,891 | 123,791.00 | direct | yes | |
| 2019-12-30 | M | 25,000 | d | 98,800 | 123,791.00 | direct | yes | ||
| 2019-12-30 | M | 25,000 | $2.90 | a | 148,791 | 123,791.00 | direct | yes | |
| 2019-12-20 | M | 25,000 | d | 139,600 | 353,969.00 | direct | yes | ||
| 2019-12-20 | M | 25,000 | $2.70 | a | 378,969 | 353,969.00 | direct | yes | |
| 2019-12-20 | S | 25,000 | $20.17 | d | 353,969 | 353,969.00 | direct | yes | |
| 2019-12-19 | M | 25,000 | $2.70 | a | 378,969 | 353,969.00 | direct | yes | |
| 2019-12-19 | M | 25,000 | d | 164,600 | 353,969.00 | direct | yes | ||
| 2019-12-19 | S | 25,000 | $20.08 | d | 353,969 | 353,969.00 | direct | yes |
